MA45747A - Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines - Google Patents

Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines

Info

Publication number
MA45747A
MA45747A MA045747A MA45747A MA45747A MA 45747 A MA45747 A MA 45747A MA 045747 A MA045747 A MA 045747A MA 45747 A MA45747 A MA 45747A MA 45747 A MA45747 A MA 45747A
Authority
MA
Morocco
Prior art keywords
cells
generation
souh
human pluripotent
functional beta
Prior art date
Application number
MA045747A
Other languages
English (en)
French (fr)
Inventor
Nicolaj Strøyer Christophersen
Ulrik Døhn
Mattias Hansson
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA45747A publication Critical patent/MA45747A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0676Pancreatic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases [EC 2.]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80Neurotransmitters; Neurohormones
    • C12N2501/845Gamma amino butyric acid [GABA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90Polysaccharides
    • C12N2501/91Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA045747A 2016-02-24 2017-02-24 Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines MA45747A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16157181 2016-02-24

Publications (1)

Publication Number Publication Date
MA45747A true MA45747A (fr) 2019-01-02

Family

ID=55588039

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045747A MA45747A (fr) 2016-02-24 2017-02-24 Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines

Country Status (7)

Country Link
US (1) US11274280B2 (enExample)
EP (1) EP3420073B1 (enExample)
JP (1) JP7123802B2 (enExample)
CN (1) CN108699515A (enExample)
ES (1) ES2967942T3 (enExample)
MA (1) MA45747A (enExample)
WO (1) WO2017144695A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014007744A (es) 2011-12-22 2015-01-12 Janssen Biotech Inc Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal.
DE112014002780B4 (de) 2013-06-11 2025-05-22 President And Fellows Of Harvard College SC-ß-Zellen und Zusammensetzungen und Verfahren zur Erzeugung der Zellen
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク,インコーポレーテツド 膵内分泌細胞内のmafa発現を強化するための小分子の使用
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
MA45747A (fr) 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
MA45502A (fr) * 2016-06-21 2019-04-24 Janssen Biotech Inc Génération de cellules bêta fonctionnelles dérivées de cellules souches pluripotentes humaines ayant une respiration mitochondriale glucose-dépendante et une réponse en sécrétion d'insuline en deux phases
AU2018330499B2 (en) 2017-09-11 2025-01-30 Novo Nordisk A/S Enrichment of NKX6.1 and C-peptide co-expressing cells derived in vitro from stem cells
AU2018370029B2 (en) 2017-11-15 2024-11-07 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
IL277025B2 (en) * 2018-03-02 2024-04-01 Vertex Pharma Methods of enhancing stem cell differentiation into beta cells
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
AU2018439389A1 (en) * 2018-08-30 2021-02-18 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
EP3953451A1 (en) 2019-04-08 2022-02-16 Novo Nordisk A/S Generation of pancreatic endoderm from stem cell derived definitive endoderm
TW202115245A (zh) 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
JP2023503302A (ja) 2019-11-22 2023-01-27 ノヴォ ノルディスク アー/エス スピン凝集した神経系マイクロスフェアおよびその応用
US20240226179A1 (en) * 2020-02-28 2024-07-11 The Trustees Of The University Of Pennsylvania Tissue culture media for survival and engraftment of human pancreatic islets
EP4114927A1 (en) 2020-03-02 2023-01-11 Novo Nordisk A/S Use of pluripotent markers to detect contaminating residual undifferentiated pluripotent stem cells
CN116018150A (zh) 2020-08-28 2023-04-25 诺和诺德股份有限公司 用于筛选干细胞衍生的β样细胞的体外群体的方法及其新型标志物
AR124419A1 (es) 2020-12-18 2023-03-29 Novo Nordisk As Células seguras invisibles para el sistema inmunitario
WO2022136215A1 (en) 2020-12-21 2022-06-30 Novo Nordisk A/S Safe immuno-stealth cells
CN113069440A (zh) * 2021-04-08 2021-07-06 澳门大学 甲状腺素的新的应用、培养多能干细胞的方法和培养基
WO2023076554A1 (en) * 2021-10-28 2023-05-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for promoting in vitro maturation of cells
WO2023118050A1 (en) 2021-12-21 2023-06-29 Novo Nordisk A/S Use of novel markers to detect pluripotent stem cells
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025093467A1 (en) 2023-10-31 2025-05-08 Novo Nordisk A/S Methods for preventing unwanted cells arising during differentiation of human pluripotent stem cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343786B (es) 2009-12-23 2016-11-22 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
EP3498825A1 (en) 2010-05-12 2019-06-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US20140234963A1 (en) 2011-06-21 2014-08-21 Novo Nordisk A/S Efficient induction of definitive endoderm from pluripotent stem cells
AU2013255031C1 (en) * 2012-04-30 2018-12-06 University Health Network Methods and compositions for generating pancreatic progenitors and functional beta cells from hPSCs
WO2014033322A1 (en) * 2012-09-03 2014-03-06 Novo Nordisk A/S Generation of pancreatic endoderm from pluripotent stem cells using small molecules
EP2900820B2 (en) 2012-09-27 2020-11-18 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for producing a population of pancreatic beta-cells
ES2942484T3 (es) 2012-12-31 2023-06-01 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas usando reguladores de HB9
US20150368616A1 (en) 2013-02-14 2015-12-24 The Cleveland Clinic Foundation Methods for induction of cell fates from pluripotent cells
JP2016521971A (ja) 2013-04-23 2016-07-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法119条第(e)項に基づき、2014年1月29日出願の米国特許仮出願第61/932,935号、2013年9月17日出願の米国特許仮出願第61/878,769号、および2013年4月23日出願の米国特許仮出願第61/814,920号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、YaqubHANNA、NoaNOVERSHTERN、およびYoachRAISによる米国特許出願(発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法(ISOLATEDNAIVEPLURIPOTENTSTEMCELLSANDMETHODSOFGENERATINGSAME)」)(代理人事件記録簿第58870号)にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。
WO2014179198A1 (en) 2013-04-29 2014-11-06 Wisconsin Alumni Research Foundation Methods for producing insulin-secreting beta cells from human pluripotent stem cells
DE112014002780B4 (de) 2013-06-11 2025-05-22 President And Fellows Of Harvard College SC-ß-Zellen und Zusammensetzungen und Verfahren zur Erzeugung der Zellen
US20160208215A1 (en) * 2013-08-30 2016-07-21 Novo Nordisk A/S Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules
US20150250824A1 (en) * 2014-03-07 2015-09-10 The Research Foundation For The State University Of New York Methods and compositions for expansion of stem cells and other cells
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク,インコーポレーテツド 膵内分泌細胞内のmafa発現を強化するための小分子の使用
MA45747A (fr) 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
AU2018439389A1 (en) 2018-08-30 2021-02-18 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors

Also Published As

Publication number Publication date
EP3420073A1 (en) 2019-01-02
US11274280B2 (en) 2022-03-15
EP3420073C0 (en) 2023-11-08
EP3420073B1 (en) 2023-11-08
WO2017144695A1 (en) 2017-08-31
ES2967942T3 (es) 2024-05-06
JP7123802B2 (ja) 2022-08-23
WO2017144695A9 (en) 2017-10-19
JP2019510482A (ja) 2019-04-18
CN108699515A (zh) 2018-10-23
US20190085295A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
MA45747A (fr) Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
CL2018001223A1 (es) Locus óptimo de la soja (divisional de solicitud 201601063)
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MX394516B (es) Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
ECSP13012877A (es) FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX390083B (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MA51107A (fr) Cellules souches et progénitrices hématopoïétiques humaines cd34+ modifiées par crispr-cas9 et utilisations associées
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
EA201991798A1 (ru) Стабильные при хранении составы
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
BR112022001207A2 (pt) Método de obtenção de mitocôndrias de células e mitocôndrias obtidas
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX2019015868A (es) Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima.
BR112019021300A8 (pt) Composições de fragrâncias e produtos com efeitos de melhora do humor
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.